Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 288

1.

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000.

PMID:
21182345
[PubMed - indexed for MEDLINE]
2.

Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Hill AM, Gebo K, Hemmett L, Löthgren M, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:169-81. doi: 10.2165/11587510-000000000-00000.

PMID:
21182350
[PubMed - indexed for MEDLINE]
3.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
[PubMed - indexed for MEDLINE]
4.

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Mauskopf J, Brogan A, Martin S, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000.

PMID:
21182346
[PubMed - indexed for MEDLINE]
5.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
[PubMed - indexed for MEDLINE]
6.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:107-28. doi: 10.2165/11587480-000000000-00000.

PMID:
21182347
[PubMed - indexed for MEDLINE]
7.

A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Mauskopf J, Annemans L, Hill AM, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:1-16. doi: 10.2165/11587410-000000000-00000. Review.

PMID:
21182340
[PubMed - indexed for MEDLINE]
8.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
[PubMed - indexed for MEDLINE]
9.

Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.

Colin X, Lafuma A, Costagliola D, Smets E, Mauskopf J, Guillon P.

Pharmacoeconomics. 2010;28 Suppl 1:183-97. doi: 10.2165/11587520-000000000-00000.

PMID:
21182351
[PubMed - indexed for MEDLINE]
10.

Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.

Gazzard B, Hill A, Anceau A.

Appl Health Econ Health Policy. 2011 Jul 1;9(4):217-23. doi: 10.2165/11592220-000000000-00000.

PMID:
21682350
[PubMed - indexed for MEDLINE]
11.

Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.

Hill A, Hemmett L, Wilson B.

HIV Clin Trials. 2007 Sep-Oct;8(5):303-10.

PMID:
17956831
[PubMed - indexed for MEDLINE]
Free Article
12.

Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

Ruof J, Dusek A, DeSpirito M, Demasi RA.

Clin Drug Investig. 2007;27(7):469-79.

PMID:
17563127
[PubMed - indexed for MEDLINE]
13.
14.

Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

Delaugerre C, Buyck JF, Peytavin G, Viard JP, Chaix ML, Zucman D, Mortier E, Blanche S, Rouveix E, Force G, Aegerter P, de Truchis P.

J Clin Virol. 2010 Mar;47(3):248-52. doi: 10.1016/j.jcv.2009.12.022. Epub 2010 Jan 22.

PMID:
20097121
[PubMed - indexed for MEDLINE]
15.

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C.

HIV Med. 2012 Aug;13(7):398-405. doi: 10.1111/j.1468-1293.2012.00989.x. Epub 2012 Mar 14.

PMID:
22413874
[PubMed - indexed for MEDLINE]
16.

Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.

Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E.

HIV Clin Trials. 2010 May-Jun;11(3):133-44. doi: 10.1310/hct1103-133.

PMID:
20736150
[PubMed - indexed for MEDLINE]
17.

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.

AIDS. 2009 Sep 10;23(14):1829-40. doi: 10.1097/QAD.0b013e32832cbcec.

PMID:
19474650
[PubMed - indexed for MEDLINE]
18.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C.

AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944.

PMID:
20010070
[PubMed - indexed for MEDLINE]
19.

The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.

Hill AM, Cho M, Mrus JM.

AIDS Rev. 2011 Jan-Mar;13(1):41-8. Review.

PMID:
21412388
[PubMed - indexed for MEDLINE]
20.

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C.

Antivir Ther. 2011;16(1):59-65. doi: 10.3851/IMP1710.

PMID:
21311109
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk